BACKGROUND
Basal cell carcinomas (BCCs) can be categorized as aggressive or nonaggressive based on their histology 1,2 -Most BCCs have nonaggressive histology, including superficial and nodular subtypes 2 -Aggressive subtypes (eg, micronodular, infiltrative, or sclerosing) are rarer but tend to have a higher rate of recurrence 1,2 Sonidegib (LDE225) is a hedgehog (Hh) pathway inhibitor approved for the treatment of patients with locally advanced BCC (laBCC) not amenable to surgery or radiotherapy [3] [4] [5] -Sonidegib was approved based on results from the phase 2 Basal Cell Carcinoma Outcomes With LDE225 Treatment (BOLT) study (NCT01327053), which included patients with aggressive or nonaggressive laBCC subtypes 6 
OBJECTIVE
In patients with laBCC regardless of tumor aggressiveness, durable tumor responses were observed -These results are significant, given the higher rate of recurrence and higher chance of subclinical spread associated with aggressive laBCC subtypes Here we present the efficacy and safety of sonidegib 200 mg in patients with laBCC, based on tumor aggressiveness, from the BOLT 30-month analysis
METHODS
BOLT was a multicenter, randomized, double-blind, phase 2 study that enrolled patients with laBCC (aggressive or nonaggressive) or metastatic BCC (mBCC; Figure 1 ) Patients with laBCC not amenable to curative surgery or radiotherapy were randomized in a 1:2 ratio to 200 mg or 800 mg once daily (QD); only results from the 200-mg QD dose will be discussed here Objective response rate (ORR: confirmed complete response [CR] + partial response [PR] ). Duration of response, and progression-free survival (PFS) were assessed according to stringent criteria, defined as modified Response Evaluation Criteria In Solid Tumors (mRECIST; Figure 2) , by central review -Overall survival (OS) was also assessed Safety was assessed until 30 days after the final treatment; Common Terminology Criteria for Adverse Events (CTCAE) v4.03 guidelines were used to evaluate adverse events (AEs) 6 
Progression and Survival
PFS and OS were similar for patients with aggressive or nonaggressive laBCC subtypes ( Table 2 ) Overall, 5 deaths in patients with laBCC in the 200-mg arm were reported by the data cutoff date Median OS was not reached for either histological subgroup in either arm
Safety
The observed safety profile of sonidegib remained similar to that of previous analyses, with the 200-mg dose continuing to show a favorable profile 7, 8, 10 >50% of patients with laBCC experienced grade 1/2 AEs The most common AEs of any grade among patients with laBCC were muscle spasms, alopecia, dysgeusia, and nausea (Figure 4 ) There were no treatment-related deaths There were no significant differences noted between the subtypes 
CONCLUSIONS

